Additional 100,000 vials of Remdesivir for COVID-19 treatment arrive in Vietnam
Approximately 100,000 vials of Remdesivir produced by Mylan pharmaceutical company under Pfizer group have arrived in Vietnam in order to treat COVID-19 patients.
The latest batch is being delivered under the sponsorship order of DB Group, the founding shareholder of Ecopark Group.
The shipment has been delivered to various localities nationwide that have been severely impacted by the coronavirus pandemic.
A representative of Ecopark Group revealed that a further batch of 100,000 vials of Remdesivir will also be transported to the nation in the near future as part of treating COVID-19 patients suffering from severe conditions caused by the disease.
Moving forward, the 200,000 vials of Remdesivir are anticipated to help localities provide effective treatment for between 20,000 and 30,000 coronavirus patients.
Remdesivir is an anti-virus drug that was granted approval by the Food and Drug Administration (FDA) of the United States to treat COVID-19 patients back in October 22, 2020.
Having the ability to shorten the treatment time and speed up the recovery of patients whose condition is severe, Remdesivir has been included in the treatment regimens of 50 countries, including the US, the EU, Australia, Japan, Singapore, and India, and it has since become one of the leading hard-to-access specialised drugs in the world.
